

EXECUTIVE MANAGEMENT TEAM

> **John McBride – Executive Vice President and Chief Operating Officer**

Mr. McBride is a 20-year veteran of the biotechnology and pharmaceutical industry. Prior to joining Gloucester Pharmaceuticals, he was a business development consultant providing services to clients on a variety of business development issues including the development of business development strategy, identification and evaluation of possible licensing and product acquisition opportunities and transactional support. Prior to starting his consulting practice Mr. McBride was Global Head of Oncology Licensing at Pharmacia Corporation. There he was responsible for the Company's oncology licensing activities including the development of the Company's oncology licensing strategy and oncology-related in-license, out-license and product divestiture transactions. Before Pharmacia he served as Executive Vice President, Business Operations and Chief Financial Officer at CytoTherapeutics, Inc. Mr. McBride's previous positions include Vice President, Business Development and Treasurer at Phytera, Inc., Vice President, Commercial Development at Sparta Pharmaceuticals, Vice President, Business Development at US Bioscience, and various positions with Eastman Kodak and Atlantic Richfield Company. Mr. McBride has a BS in Biochemistry and an MS in Chemical Engineering from the University of Wisconsin and an MBA from the Wharton School, University of Pennsylvania.

> **William McCulloch, MB, FRCP, FFPM – Executive Vice President and Chief Medical Officer**

Dr. McCulloch most recently was President of Alba Biopharma Advisors, a clinical development consulting firm he founded in 2002. Prior to founding Alba, Dr. McCulloch served as the Executive Vice President & Medical Director of A.M. Pappas & Associates, LLC, a North Carolina life sciences venture development firm (now Pappas Ventures). At Pappas, he developed and managed the company's international pharmaceutical and biotechnology advisory practice, with clients ranging from large pharmaceutical firms to start-up companies. In addition, he provided due diligence and other services in support of the company's significant venture capital activities. Dr. McCulloch's previous U.S. appointments were as Senior Vice President of R&D for Sparta Pharmaceuticals, and Vice President of Clinical R&D for U.S. Bioscience. While residing in Europe, he held senior executive positions with Bristol-Myers Co., Celltech Ltd., and Astra Alab, a division of Astra AB (now Astra Zeneca). Dr. McCulloch earned his M.B., Ch.B. (M.D. equivalent) from the University of Glasgow in Scotland, is a Member of the Royal College of Physicians (UK),

a Fellow of the Royal College of Physicians (Glasgow) and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the UK. In addition, he holds a Diploma from the Royal College of Obstetricians and Gynaecologists, as well as a Diploma in Pharmaceutical Medicine, both from the U.K. He is a member of the American Society of Clinical Oncology.

➤ **Jean Nichols, PhD – Executive Vice President and Chief Scientific Officer**

Dr. Jean Nichols is a biopharmaceutical industry executive with operating, technical, development, general management and fundraising experience. She was responsible for development of ONTAK®, a drug to treat lymphoma and leukemia, from concept to market, directing all product development activities, manufacturing, clinical trials and regulatory affairs. Her research experience includes infectious diseases, biochemistry, molecular genetics, drug delivery and diagnostics. Dr. Nichols' previous positions include President and Chief Scientific Officer of Seragen, Inc., Managing Director and Chief Operating Officer of StoneGate Partners, LLC, and most recently as a consultant specializing in strategic positioning and execution of product development programs for biopharmaceutical companies by providing senior management or advisory services. Dr. Nichols has been involved in raising more than \$250 million from private investors, venture capitalists, initial and secondary public offerings, corporate partnerships and a merger. Dr. Nichols received both her B.S. in biology and Ph.D. in Bacteriology and Immunology from the University of North Carolina at Chapel Hill. She completed her postdoctoral training at Harvard Medical School and served as a member of junior faculty. Dr. Nichols is an inventor on five patents and has authored 40 articles on infectious diseases and pre-clinical and clinical studies in the field of fusion proteins.

➤ **Nicholas Vrolijk, PhD – Vice President Manufacturing Operations**

Dr. Vrolijk was a founding partner of Pharmaceutical Manufacturing & Compliance Associates. He has held management positions in quality assurance, regulatory compliance, and manufacturing operations at Pharmacia and Sensus Drug Development Corp. Prior to this, Dr. Vrolijk was a Regulatory Scientist at Cato Research, a contract research organization (CRO), and was responsible as project leader for managing and directing non-clinical, clinical, and manufacturing activities for a range of development projects. Dr. Vrolijk received a BS in Biology and Geology from the University of Rochester, and a Masters and Ph.D. in Marine Biochemistry from the University of Delaware. He performed post-doctoral work at the University of Maryland and the University of Connecticut, which were supported by a National Science Foundation molecular biology training grant and a National Institutes of Health research grant, respectively.



➤ **Mitchell Keegan, Ph.D. – Senior Director, Drug Development**

Dr. Keegan is an accomplished pharmacologist with ten years of progressive research and organizational leadership experience. Previously, he was Director of Pharmacology at CombinatoRx, Inc., where he directed the company's pharmacology department and participated on development teams for products in the areas of oncology, diabetes and inflammation. Prior to that, he managed the genetic toxicology department at Toxikon Corporation, and was a research fellow at the Harvard Medical School/Joslin Diabetes Center. Dr. Keegan received a BS from the University of Sydney in Australia and his PhD in molecular and cellular biology from the University of Western Sydney in Australia.

➤ **Brian Wiley – Senior Director, Marketing and Business Planning**

Mr. Wiley has over ten years of commercial oncology experience with a variety of products including Taxotere®, Velcade®, Oncaspar®, Gliadel Wafer® and Anzemet®. Most recently, he served as Associate Director, Market Planning and Development at Millennium Pharmaceuticals where he focused on strategic and pre-market planning for Velcade in emerging indications. Mr. Wiley's previous experience includes a diverse 12 year tenure at Aventis Pharmaceuticals (now Sanofi-Aventis), including management positions in marketing, national accounts & sales. In his most recent position as Senior Manager, Oncology Networks he developed and implemented contracting strategies for over \$900 million in annual oncology product sales for Taxotere and Anzemet. He was also instrumental in the successful launch of Taxotere in the non-small cell lung cancer (NSCLC) market. Mr. Wiley received a BA from The Pennsylvania State University and completed graduate level coursework at the University of New Mexico.

